Parameter | Description | Value (range) | Source |
---|---|---|---|
R 0 | basic reproduction number | 1.07 (0.55–1.99) 2.6 (1–7) | [14] [34] |
r | hospital admission rate | 0.17 day−1 | assumed to be the same as discharge rate |
δ | fraction of admitted patients with CDI symptoms | 1.2 × 10−4 | Calculated based on the rate of 6.9 per 10,000 patient-days estimated over 82 periods of 4 weeks [20] |
θ | fraction of admitted patients without CDI symptoms who are screened | 0.925 (0–1) | [20] |
b s | fraction of screened admitted patients who are susceptible | 0.952 (0–1) | [20] |
η | fraction of screened patients who are colonized and develop immune responses | 0.6 (0.45–0.75) | |
α | fraction of screened admitted patients who are susceptible and receive antibiotic treatment | 0.22 (0.15–0.29) | [14] |
σ | fraction of in-hospital patients who are screened following exposure to CDI | 0.9 (0–1) | assumed, varied in sensitivity analysis |
f | fraction of colonized patients who develop immune responses | 0.6 (0.45–0.75) | |
ε | rate of developing CDI symptoms in colonized patients | 0.2 (0.14–0.26) day−1 | |
τ + | recovery rate of damaged gut flora | 0.011 day−1 | [37] |
τ − | rate of antibiotic treatment damaging gut flora | 0.11 day−1 | [36] |
q | fraction of CDI patients who are successfully treated | 0.8 (0.56–1) | |
μ | discharge rate of hospital patients without symptomatic infection | 0.17 day−1 | |
μ I | CDI-caused death rate | 0.0012 (0.001–0.01) day−1 | |
ρ | rate of symptoms resolution for CDI patients under treatment | 0.25 (0.143–0.33) day−1 | [35] |
γ | recovery rate of CDI patients under treatment after symptoms resolution | 0.2 (0.143–0.33) day−1 | |
κ | relative transmissibility of colonized patients without symptoms | 0.5 (0.3–0.7) | assumed, varied in sensitivity analysis |
ν | reduction of transmissibility due to immune responses | 0.5 (0.3–0.7) | assumed, varied in sensitivity analysis |
ξ | effectiveness of isolation for CDI patients | 0.8, 0.9, 1 (0.8–1) | assumed, varied in sensitivity analysis |
Ψ | reduced risk of CDI in patients without antibiotic exposure | 0.2 (0.06–0.55) | [24] |
π | time-interval between sample collection and release of laboratory results | 1 (1–3) days |